Wegovy 10mg: what the evidence actually shows about this dose

What the MHRA-approved Wegovy schedule actually looks like

The MHRA has authorised semaglutide (Wegovy) for weight management in adults with a BMI of 30 or above, or 27–29.9 alongside at least one weight-related condition. The licensed titration pathway begins at 0.25mg once weekly, moving through 0.5mg, 1.0mg, and 1.7mg before reaching the standard 2.4mg maintenance dose, each step typically held for around four weeks to allow the body to adjust. In January 2026 a higher 7.2mg dose received authorisation, initially delivered as three 2.4mg pens per week; by April 2026 the MHRA approved a dedicated single-dose 7.2mg pen designed with a covered needle that locks after use. No 10mg strength has been assessed, submitted or authorised for Wegovy in the UK, and you can find a full breakdown of what semaglutide 10 means in the context of online searches if you want more detail on why that figure circulates. The schedule is fixed by regulatory approval and clinical evidence, not by demand.

It's a question our prescribers hear most weeks: patients who have done their research sometimes arrive convinced a higher or different dose must be available somewhere. The honest answer is that the numbers in the licensed schedule are there because those are exactly the strengths studied in the clinical trials that underpinned approval.

Where the "10" confusion probably comes from

There are a few understandable sources of confusion. First, Rybelsus (also semaglutide, made by the same manufacturer) is licensed for type 2 diabetes and comes in 3mg, 7mg and 14mg oral tablets. Rybelsus is not a weight-loss medicine and its strength range has no relationship to Wegovy's injection schedule. Second, some compounding services operating outside the licensed supply chain have offered semaglutide in non-standard concentrations or volumes, sometimes described in milligrams per millilitre rather than per dose; this has led to figures like "10 units" or "10ml" appearing in online searches, and our page on what 10 units of semaglutide actually refers to explains why that measurement doesn't correspond to any authorised Wegovy dose. Those products are not MHRA-authorised formulations of Wegovy. If you've encountered references to 10ml semaglutide or similar descriptions, those almost certainly relate to unlicensed compounded preparations rather than the regulated medicine. Third, US readers may encounter tirzepatide under the brand name Zepbound in American sources, which has its own separate strength ladder, that product does not exist in the UK, where the same active ingredient is sold as Mounjaro.

Staying within the licensed UK supply chain matters. You can read more about how semaglutide works as a medicine and why the distinction between licensed and unlicensed preparations is clinically significant.

What the trial evidence shows at the doses that are licensed

The STEP 1 trial, published in the New England Journal of Medicine, studied 68 weeks of semaglutide 2.4mg once weekly in adults with obesity or overweight alongside at least one weight-related condition. Average body weight fell by around 15%, a result that shifted the clinical conversation about what medication-assisted weight management could achieve. The 7.2mg data, from later phase 3 work, reported approximately 20.7% average weight loss at 72 weeks, approaching the figures seen with the highest tirzepatide dose in the SURMOUNT programme. These are population averages from controlled trials; individual outcomes vary, and a prescriber will discuss what is realistic for your situation. Results also depend on the lifestyle changes that both Wegovy's licence and NICE's guidance treat as non-negotiable companions to the medicine.

NICE's recommendation for semaglutide (TA875) is specific about context: the medicine should be used for a maximum of two years, within a specialist weight management service that includes multidisciplinary support, and treatment should be reviewed if less than 5% weight loss is achieved after six months at the maintenance dose. For a broader look at the full Wegovy treatment picture, the Wegovy overview page covers eligibility, how to access it privately, and what clinical review involves.

Eligibility, safety and what comes after the search

Because Wegovy is a prescription-only medicine, the dose you take (whether 0.25mg at the start or 2.4mg or beyond) is decided by a qualified prescriber who has reviewed your full health picture. BMI alone does not determine the right dose or even suitability; conditions including pancreatitis history, certain thyroid conditions, and pregnancy all affect whether and how treatment can proceed. The NHS semaglutide patient information page lists the key contraindications and side effects in plain language and is a reliable starting point. Common side effects are mostly gastrointestinal (nausea, constipation, diarrhoea) and tend to be most noticeable in the early weeks or after a dose increase, generally settling as the body adapts.

Semaglutide is not recommended during pregnancy, while breastfeeding, or for anyone under 18. If you are of childbearing age, contraception guidance is part of the clinical picture your prescriber will cover. For those considering private treatment, the options for accessing Wegovy through a regulated UK pharmacy are worth understanding before making a decision. Any pharmacy dispensing these medicines legally must be registered with the GPhC, you can verify a pharmacy on the GPhC register before you proceed. If you'd like to understand your own eligibility, the free consultation at nume is reviewed the same day by a GPhC-registered Independent Prescriber. Check your eligibility at our treatment page.